Details for Patent: 9,913,842

Title:	2,4-pyrimidinediamine compounds and their uses
Abstract:	The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Inventor(s):	Singh; Rajinder (Belmont, CA), Argade; Ankush (Foster City, CA), Payan; Donald (Hillsborough, CA), Molineaux; Susan (South San Francisco, CA), Holland; Sacha (San Francisco, CA), Clough; Jeffrey (Redwood City, CA), Keim; Holger (Irvine, CA), Bhamidipati; Somasekhar (Foster City, CA), Sylvain; Catherine (San Mateo, CA), Li; Hui (Santa Clara, CA), Rossi; Alexander (Reedsport, OR)
Assignee:	Rigel Pharmaceuticals, Inc. (South San Francisco, CA)
Filing Date:	Jul 08, 2016
Application Number:	15/205,725
Claims:	1. A method of inhibiting Syk kinase in a cell, the method comprising causing the cell to be contacted with an effective amount of a compound according to the formula: ##STR00051## or a salt thereof, wherein: R.sup.2 is selected from phenyl mono-substituted at the 3- or 5-position with an R.sup.8 group and phenyl di- or tri-substituted with the same or different R.sup.8 groups, provided R.sup.2 is not 3,4,5-trimethoxyphenyl; R.sup.4 is phenyl substituted with one or more of the same or different R.sup.8 groups; R.sup.2 and R.sup.4 are different; R.sup.5 is halogen; R.sup.6 is hydrogen; each R.sup.8 is selected from the group consisting of R.sup.a, R.sup.b, --O--(CH.sub.2).sub.m--R.sup.b--C(O)NH--(CH.sub.2).sub.m--R.sup.b, --C(O)NH--(CHR.sup.a).sub.m--R.sup.b, --O--(CH.sub.2).sub.m--C(O)NH--(CH.sub.2).sub.m--R.sup.b, --O--(CHR.sup.a).sub.m--C(O)NH--(CHR.sup.a).sub.m--R.sup.b, --NH--(CH.sub.2).sub.m--R.sup.b, --NH--(CHR.sup.a).sub.m--R.sup.b; each R.sup.a is independently selected from the group consisting of (C.sub.1-C.sub.6) alkyl, (C.sub.3-C.sub.8) cycloalkyl, cyclohexyl, phenyl, (C.sub.6-C.sub.16) arylalkyl, benzyl, 1, 3-8 membered cycloheteroalkyl, morpholinyl, 4-11 membered cycloheteroalkylalkyl and 5-10 membered heteroaryl; each R.sup.b is independently selected from the group consisting of --OR.sup.d, (C.sub.1-C.sub.3) haloalkyloxy, halogen, --CF.sub.3, --S(O)R.sup.d, --S(O).sub.2R.sup.d, --S(O).sub.2OR.sup.d, --S(O).sub.2NR.sup.cR.sup.c, --OS(O)R.sup.d, --OS(O).sub.2R.sup.d, --OS(O).sub.2OR.sup.d, --OS(O).sub.2NR.sup.cR.sup.c, --C(O)R.sup.d, --C(O)OR.sup.d, --C(O)NR.sup.cR.sup.c, --OC(O)R.sup.d, --OC(O)OR.sup.d, --OC(O)NR.sup.cR.sup.c, --OC(NH)NR.sup.cR.sup.c; each R.sup.c is independently hydrogen or R.sup.a; each R.sup.d is independently hydrogen or R.sup.a; and each m is independently an integer from 1 to 3. 2. The method of claim 1, wherein R.sup.2 is phenyl di-substituted with the same or different R.sup.8 groups. 3. The method of claim 1, wherein R.sup.2 is 3,4-disubstituted. 4. The method of claim 1, wherein R.sup.4 is mono-substituted with an R.sup.8 group. 5. The method of claim 4, wherein R.sup.4 is ortho-substituted with the R.sup.8 group. 6. The method of claim 4, wherein R.sup.4 is meta-substituted with the R.sup.8 group. 7. The method of claim 4, wherein R.sup.4 is para-substituted with the R.sup.8 group. 8. The method of claim 1, wherein R.sup.5 is fluoro. 9. The method according to claim 1 wherein the compound is administered in a composition comprising the compound and a pharmaceutically acceptable carrier, diluent or excipient. 10. The method of claim 9, wherein the compound is in the form of a pharmaceutically acceptable salt. 11. The method of claim 5, wherein R.sup.5 is fluoro. 12. The method of claim 5, wherein R.sup.5 is chloro. 13. The method of claim 1, wherein R.sup.2 is phenyl tri-substituted with the same or different R.sup.8 groups. 14. The method of claim 13, wherein R.sup.4 is mono-substituted with an R.sup.8 group. 15. The method of claim 14, wherein R.sup.4 is ortho-substituted with the R.sup.8 group. 16. The method of claim 14, wherein R.sup.4 is meta-substituted with the R.sup.8 group. 17. The method of claim 14, wherein R.sup.4 is para-substituted with the R.sup.8 group. 18. The method of claim 14, wherein R.sup.5 is fluoro. 19. The method of claim 14, wherein R.sup.5 is chloro. 20. A method of treating a disease mediated by an Fc receptor signaling cascade, wherein the disease is inflammation and inflammatory disease, low grade scarring, sicca complex or syndrome, or a cardiac disease in a subject in need thereof, the method comprising administering to the subject an effective amount of compound according to the formula: ##STR00052## or a salt thereof, wherein: R.sup.2 is selected from phenyl mono-substituted at the 3- or 5-position with an R.sup.8 group and phenyl di- or tri-substituted with the same or different R.sup.8 groups, provided R.sup.2 is not 3,4,5-trimethoxyphenyl; R.sup.4 is phenyl substituted with one or more of the same or different R.sup.8 groups; R.sup.2 and R.sup.4 are different; R.sup.5 is halogen; R.sup.6 is hydrogen; each R.sup.8 is selected from the group consisting of R.sup.a, R.sup.b, --O--(CH.sub.2).sub.m--R.sup.b-C(O)NH--(CH.sub.2).sub.m--R.sup.b- , --C(O)NH--(CHR.sup.a).sub.m--R.sup.b, --O--(CH.sub.2).sub.m--C(O)NH--(CH.sub.2).sub.m--R.sup.b, --O--(CHR.sup.a).sub.m--C(O)NH--(CHR.sup.a).sub.m--R.sup.b, --NH--(CH.sub.2).sub.m--R.sup.b, --NH--(CHR.sup.a).sub.m--R.sup.b, --; each R.sup.a is independently selected from the group consisting of (C.sub.1-C.sub.6) alkyl, (C.sub.3-C.sub.8) cycloalkyl, cyclohexyl, phenyl, (C.sub.6-C.sub.16) arylalkyl, benzyl, 1, 3-8 membered cycloheteroalkyl, morpholinyl, 4-11 membered cycloheteroalkylalkyl and 5-10 membered heteroaryl; each R.sup.b is independently selected from the group consisting of --OR.sup.d, (C.sub.1-C.sub.3) haloalkyloxy, halogen, --CF.sub.3, --S(O)R.sup.d, --S(O).sub.2R.sup.d, --S(O).sub.2OR.sup.d, --S(O).sub.2NR.sup.cR.sup.c, --OS(O)R.sup.d, --OS(O).sub.2R.sup.d, --OS(O).sub.2OR.sup.d, --OS(O).sub.2NR.sup.cR.sup.c, --C(O)R.sup.d, --C(O)OR.sup.d, --C(O)NR.sup.cR.sup.c, --OC(O)R.sup.d, --OC(O)OR.sup.d, --OC(O)NR.sup.cR.sup.c, --OC(NH)NR.sup.cR.sup.c; each R.sup.c is independently hydrogen or R.sup.a; each R.sup.d is independently hydrogen or R.sup.a; and each m is independently an integer from 1 to 3. 21. The method of claim 20, wherein the inflammatory disease is osteoarthritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, idiopathic inflammatory bowel disease, irritable bowel syndrome, or spastic colon. 22. The method of claim 20, wherein the low grade scarring is scleroderma, increased fibrosis, keloids, post-surgical scars, pulmonary fibrosis, vascular spasms, migraine, reperfusion injury or post myocardial infarction. 23. The method of claim 20, wherein R.sup.2 is phenyl tri-substituted with the same or different R.sup.8 groups. 24. The method of claim 23, wherein R.sup.4 is mono-substituted with an R.sup.8 group. 25. The method of claim 24, wherein R.sup.5 is fluoro. 26. The method of claim 20, wherein R.sup.2 is phenyl tri-substituted with the same or different R.sup.8 groups. 27. The method of claim 26, wherein R.sup.4 is mono-substituted with an R.sup.8 group. 28. The method of claim 27, wherein R.sup.5 is fluoro.